Therefore, the open space remains. A biologic that provides high immediacy and high durability at the same time and in the same therapy has the potential to be a heavy weight in this important $15+ billion marketplace Mainstay intravitreal biologic monotherapies for all patients Gen 1.0 • Eylea • Lucentis • Biosimilars Gen 1.5 • Eylea HD • Vabysmo Onerous monitoring and inflammation control. Long-term safety unknown Maintenance agents to be used in subset of patients but always relying on mainstay biologics to (re)establish disease control Implants Gene Therapies Efficacy Durability High Immediacy + High Durability At the same time and in the same product A biologic that provides: 15